PubMed · 14160139
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J C LILLIE. 1964. PULMONARY FUNCTION BEFORE AND AFTER ARYTENOIDECTOMY.. https://doi.org/10.1001/archotol.1964.00750040176012
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
In response to mass media's role in the national and global system of pharmaceutical risk communication, the Centers for Education and Research on Therapeutics (CERTs) convened a 'think tank' session on the 'Importance of Media in Pharmaceutical Risk Communication'. Prominent journalists and experts from the pharmaceutical industry, academia, medical practice and government were invited to consider the benefits and challenges of improving the way we communicate the benefits and risks of therapeutics via mass media, especially news media. Workshop discussions revealed a paucity of systematic research directed towards understanding how and why news media report on therapeutic risk, the impact of this coverage and how coverage can be improved. Consequently, participants produced a research agenda capturing the key aspects of the flow of information around this topic, including the meaning of risk, how news audiences process and use therapeutic risk information in the news, how and why news organizations report on therapeutic risk, and the role and impact of the pharmaceutical industry, government officials and academic researchers as sources of therapeutic risk information. The workshop ended with a discussion on action items addressing what news professionals, representatives of regulatory agencies and the medical products industry, and academic researchers can and should do to enable news media to effectively report therapeutic risk information. In sum, this proceedings report provides an outline for developing mass media risk communication research, influencing the practices of journalists and expert sources and ultimately, improving the quality of the public's life.
The role of religion and spirituality in health has received increasing attention in the scientific and lay literature. While the scientific attention to this issue has expanded, there continue to be methodological and measurement concerns that often prevent firm conclusions about health and adjustment benefits. Limited attention has been provided to the role of spirituality and religion in cancer. This is true when both disease outcome and adjustment are considered. A recent 'levels of evidence' review examining the link between physical health and religion or spirituality found little overall support for the hypotheses that religion or spirituality impact cancer progression or mortality. Studies examining their impact on quality of life and adjustment are decidedly mixed. In sum, research specifically focusing on the role of religion or spirituality on cancer outcomes has been surprisingly sparse. Such research presents a number of methodological and measurement challenges. Due to these unmet challenges in the literature to date, it is premature to determine what role religion and spirituality play in disease, adjustment, or quality of life outcomes in cancer. A number of suggestions are made for continued research in this area.
3-Hydroxy-3-methyglutaryl coenzyme A (HMG-CoA) reductase inhibitors, "statins," are widely used oral cholesterol-lowering drugs. Statins competitively inhibit HMG-CoA reductase, the enzyme that catalyzes conversion of HMG-CoA to L-mevalonate, a key intermediate in cholesterol synthesis. Certain metabolites of L-mevalonate are also involved in posttranslational modifications of specific proteins with cell proliferation and differentiation properties. Thus, statins have important biologic effects beyond their cholesterol-reducing properties. Here we discuss recent experimental and clinical data that may support a potential role for statins in the treatment of three central nervous system (CNS) neurological diseases: Multiple sclerosis (MS), Alzheimer's disease (AD), and ischemic stroke. Despite their considerable pathogenic differences, in animal models of these disorders statins have shown beneficial effects. In both stroke and AD cohort studies suggest a beneficial treatment effect in humans; in MS, results from small open-label studies look encouraging. Multicenter, randomized, placebo-controlled clinical trials are in the planning or recruiting stage to evaluate the therapeutic effects of statins in all three disorders.